AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Akebia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.68+0.01 (+1.51%)
Close on Oct 19, 2026
- Market cap
- $183.36M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
83.3%+83.9 pts over 5 years
Operating margin
9.9%+138.2 pts over 5 years
Net margin
-2.3%+128.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +47.5% | -6.9% | -4.3% | – | |
| Gross profit | +102.8% | -1.7% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -136.3% | -120.8% | 64.5% | |
| Return on assets | -61.3% | -54.4% | -1.8% | |
| Current ratio | 2.59 | 1.98 | 1.55 | |
| Debt to equity | – | 0.39 | 1.48 | |
| Net debt to EBITDA | – | 0.35× | – | |
| Inventory turnover | – | 3.3× | 2.5× | |
| Capex to revenue | 173.4% | 0.1% | 0.1% | |
| Diluted shares | 38M | 138M | 257M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Akebia Therapeutics generated $458.15M from operations and spent $497.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$458.15M
Used
$497.00K
Capital expenditure$497.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2.3%
×Asset turnover0.79×
×Equity multiplier-36.03×
=Return on equity, FY202564.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -2.3% | 0.79× | -36.03× | 64.5% |
| FY2024 | -43.3% | 0.69× | -5.80× | 174.0% |
| FY2023 | -26.7% | 0.65× | -23.58× | 409.6% |
| FY2022 | -32.2% | 0.66× | 11.17× | -237.8% |
| FY2021 | -133.3% | 0.36× | 3.69× | -177.2% |
| FY2020 | -130.6% | 0.42× | 2.22× | -120.8% |
| FY2019 | -83.5% | 0.38× | 1.72× | -54.4% |
| FY2018 | -69.1% | 0.31× | 1.79× | -37.9% |
| FY2017 | -40.7% | 0.55× | 3.48× | -77.3% |
| FY2016 | -8843.5% | 0.01× | 2.23× | -136.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$5.35M
- Cash generatingOperating cash flow above zero$67.99M
- Return on assets improvedROA up on the prior year-28.7% → -2.4%
- Earnings backed by cashOperating cash flow above net income$67.99M vs -$5.35M
- Less leverageLong-term debt to assets fell17.5% → 12.8%
- Better liquidityCurrent ratio rose1.41 → 1.55
- No dilutionShare count did not rise211M → 257M
- Gross margin improvedGross margin up on the prior year60.56% → 83.29%
- More efficientAsset turnover rose0.66 → 1.07